Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration Sensitive Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06592924
What this trial is testing

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Who this might be right for
Prostate Cancer (Adenocarcinoma)
Canadian Cancer Trials Group 830
Early research (Phase 1)Looking for participantsNCT05818683
What this trial is testing

Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate NeoplasmsMetastatic Hormone-sensitive Prostate Cancer
Janssen Research & Development, LLC 300
Not applicableUnknownNCT05530395
What this trial is testing

BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC

Who this might be right for
Prostate Cancer Metastatic
Ignacio Puche Sanz 300
Large-scale testing (Phase 3)Looking for participantsNCT05956639
What this trial is testing

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The First Affiliated Hospital with Nanjing Medical University 100
Testing effectiveness (Phase 2)Looking for participantsNCT06582628
What this trial is testing

Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)

Who this might be right for
Metastatic Prostate Cancer
Fundacion Oncosur 78
Early research (Phase 1)Study completedNCT03532217
What this trial is testing

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Washington University School of Medicine 19
Testing effectiveness (Phase 2)Study completedNCT04335682
What this trial is testing

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Who this might be right for
Metastatic Prostate CancerProstate Cancer MetastaticProstate Cancer+3 more
Alliance Foundation Trials, LLC. 111
Not applicableLooking for participantsNCT06652607
What this trial is testing

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

Who this might be right for
Prostate CancerMetastatic CancerCastrate Sensitive Prostate Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 152
Not applicableLooking for participantsNCT07395804
What this trial is testing

How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Bayer 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT04126070
What this trial is testing

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Who this might be right for
Hormone Sensitive Prostate CancerProstate AdenocarcinomaMetastasis Prostate Adenocarcinoma
Xiao X. Wei, MD 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07717099
What this trial is testing

Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cance
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD 50
Not applicableLooking for participantsNCT05649943
What this trial is testing

Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 566
Post-approval studies (Phase 4)UnknownNCT04601441
What this trial is testing

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan

Who this might be right for
Metastatic Castration-sensitive Prostate Cancer
Kindai University 100
Not applicableLooking for participantsNCT07451002
What this trial is testing

Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-sensitive Prostate Cancer
Janssen Cilag S.A.S. 540
Early research (Phase 1)Study completedNCT04666129
What this trial is testing

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Sensitive Prostate CancerNon-Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc. 48
Testing effectiveness (Phase 2)Study completedNCT02058706
What this trial is testing

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
Barbara Ann Karmanos Cancer Institute 71
Early research (Phase 1)Active Not RecruitingNCT06305598
What this trial is testing

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Roswell Park Cancer Institute 3
Testing effectiveness (Phase 2)Study completedNCT00095667
What this trial is testing

Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer

Who this might be right for
Recurrent Prostate CancerStage IV Prostate Cancer
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Ended earlyNCT03827473
What this trial is testing

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer+2 more
University of Utah 1
Testing effectiveness (Phase 2)Study completedNCT05059236
What this trial is testing

Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 223
Next Page